Atlas Trials

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

Clinical trial NCT07660835 · RECRUITING

Trial details

NCT number
NCT07660835
Sponsor
Galderma R&D
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Moderate-to-Severe Atopic Dermatitis
Start date
2026-07-13
Primary completion
2028-07-15
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.